Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 18, Number 4—April 2012

Dispatch

Human Parvovirus 4 Infection, Cameroon

Myriam Lavoie, Colin P. Sharp, Jacques PépinComments to Author , Christopher Pennington, Yacouba Foupouapouognigni, Oliver G. Pybus, Richard Njouom, and Peter Simmonds
Author affiliations: Université de Sherbrooke, Sherbrooke, Quebec, Canada (M. Lavoie, J. Pépin); University of Edinburgh, Edinburgh, Scotland, UK (C.P. Sharp, C. Pennington, P. Simmonds); Centre Pasteur du Cameroun, Yaoundé, Cameroon (Y. Foupouapouognigni, R. Njouom); University of Oxford, Oxford, UK (O. Pybus)

Main Article

Table 1

Prevalence of human parvovirus 4 by patient characteristics, Cameroon, 2009*

Characteristic No. virus positive/ no. tested (%) p value
Age, y 0.04
60–64 32/125 (26)
65–69 13/96 (14)
70–74 17/103 (17)
>75 17/127 (13)
Sex 0.15
M 25/178 (14)
F 54/273 (20)
HCV serologic results 0.61
Negative 29/178 (16)
Positive 47/252 (19)
Anti-HBcAg 1.00
Negative 3/21 (14)
Positive 76/430 (18)
Treponemal antibodies 0.06
Absent 28/119 (24)
Present 51/332 (15)
Intravenous treatment for malaria 0.04
No 29/216 (13)
Yes 50/235 (21)
Intravenous treatment for other diseases 0.93
No 42/239 (18)
Yes 37/212 (17)
No. past intravenous treatments 0.38
0 12/88 (14)
1–3 33/206 (16)
>4 25/116 (22)
Unknown 9/41 (22)
Tuberculosis 0.04
No 72/433 (17)
Yes, treated with oral drugs only 4/12 (33)
Yes, treatment included
streptomycin 3/6 (50)
Transfusion 0.09
No 76/408 (19)
Yes 3/43 (7)
Depo-Provera injections† 0.006
No 50/268 (19)
Yes 4/5 (80)
Scarifications 0.88
No 30/165 (18)
Yes 49/286 (17)
Vaccine scar, left arm 0.005
Absent 17/53 (32)
Present 61/397 (15)
Vaccine scar, right arm 0.76
Absent 27/165 (16)
Present 51/284 (18)
Circumcision (males only) 0.74
Medical 9/73 (12)
Traditional 16/105 (15)

*HCV, hepatitis C virus, HBcAg, hepatitis B core antigen.
†Pharmacia & Upjohn Company, New York, NY, USA.

Main Article

TOP